Cellectar Biosciences' Iopofosine I 131, Demonstrated Complete Clonal Clearance In A Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient With CNS Involvement, Enrolled In Its Phase 2B CLOVER WaM Trial
Author: Benzinga Newsdesk | January 22, 2024 07:42am